Apellis Pharmaceuticals Inc. (APLS)
Biotech, Pharmaceuticals Samuel Bonilla Biotech, Pharmaceuticals Samuel Bonilla

Apellis Pharmaceuticals Inc. (APLS)

Apellis Pharmaceuticals, Inc. (APLS) expects data readouts from its two phase 3 studies (DERBY and OAKS) by September 2021. If positive, then patients with geographic atrophy could have a long awaited treatment options. Further, the results of these trials will have a large impact on the company’s valuation. In this blog post I share my thoughts of intravitreal pegcetacoplan phase 1b and phase 2 clinical trial data. Additionally, I share my expectations on the likelihood of seeing positive data readouts in the phase 3 DERBY and OAKS clinical trials of intravitreal pegcetacoplan in geographic atrophy (GA).

Read More
Ascendis Pharma A/S (ASND)
Biotech, Pharmaceuticals Samuel Bonilla Biotech, Pharmaceuticals Samuel Bonilla

Ascendis Pharma A/S (ASND)

Ascendis Pharma A/S (ASND) has a number of key company updates up until the first quarter of 2022. There are regulatory decisions expected from the FDA and EMA before the end of this year. However, I would like to focus on upcoming TrasCon PTH (palopegteriparatide) phase 3 data readout in adults with hypoparathyroidism expected by the first quarter of 2022.

Read More
The Pros and Cons of the Public Service Loan Forgiveness (PSLF) Program
Samuel Bonilla Samuel Bonilla

The Pros and Cons of the Public Service Loan Forgiveness (PSLF) Program

What is the PSLF (Public Service Loan Forgiveness) program? Why should I consider the PSLF program? Why should I care about the PSLF program? Do I qualify for PSLF? What are the risks that come with the PSLF program? In this post, I highlight the PSLF program and why student Pharmacists and Pharmacists should consider if the PSLF aligns with their goals.

Read More